Efficacy, Durability, and Safety of Faricimab▼ in Diabetic Macular Edema (DME): 2-Year Results From YOSEMITE and RHINE
This presentation describes 2-year results from the phase 3 YOSEMITE and RHINE trials of faricimab▼ , a dual angiopoietin-2 and VEGF-A pathway inhibitor, in patients with diabetic macular edema. YOSEMITE and RHINE compared the efficacy, safety, and durability of intravitreal faricimab▼ , administered every 8 weeks or per personalized treatment interval up to every 16 weeks, with intravitreal aflibercept administered every 8 weeks.